[CAS NO. 69-53-4] Ampicillin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [69-53-4]

Catalog

HY-B0522

Brand

MCE

CAS

69-53-4

DESCRIPTION [69-53-4]

Overview

MDL	MFCD00005175
Molecular Weight	349.40
Molecular Formula	C16H19N3O4S
SMILES	OC([C@@H]1N(C2=O)[C@]([C@@H]2NC([C@@H](C3=CC=CC=C3)N)=O)([H])SC1(C)C)=O

For research use only. We do not sell to patients.

12 Publications Citing Use of MCE

Summary

Ampicillin is a broad-spectrum beta-lactam antibiotic against a variety of gram-positive and gram-negative bacteria.

IC50 & Target

β-lactam

In Vitro

Ampicillin inhibits the growth of E. coli of swine origin in a dose-dependent manner. The effective inhibitory concentration of Ampicillin was 2.5 uG/mL ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ampicillin is very effective in alleviating the symptoms of hemorrhagic enteritis in a 11-week old pig ^[1] . Ampicillin produces maximum concentrations in bile twice as high as in serum. The peak concentration of ampicillin after an oral dose is as twice as high in portal blood as in peripheral blood ^[2] . Ampicillin provides neuroprotection against ischemia-reperfusion brain injury. Ampicillin reduces the activities of MMPs and increases the expression level of GLT-1. Pretreatment with ampicillin significantly reduces medial hippocampal cell death following global forebrain ischemia ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02819570	Western Galilee Hospital-Nahariya	Premature Rupture of Membrane	November 2015	Phase 4
NCT00021671	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institute of Mental Health (NIMH)\|National Institute on Drug Abuse (NIDA)	HIV Infections		Phase 3
NCT02424734	Pfizer\|PRA Health Sciences	Late-onset Sepsis	August 4, 2015	Phase 2
NCT04202380	Assiut University	Preterm Pre-labor Rupture of Membranes	January 2020	Not Applicable
NCT03060473	The University of Texas Medical Branch, Galveston	Preterm Premature Rupture of Membranes (PPROM)	February 23, 2017	Phase 3
NCT01994993	Michael Cohen-Wolkowiez\|The Emmes Company, LLC\|Duke University	Complicated Intra Abdominal Infections	December 2013	Phase 2\|Phase 3
NCT01945450	Hadassah Medical Organization	Endometritis	January 2014	Not Applicable
NCT03997266	Michael Morowitz\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|University of Pittsburgh	Microbial Colonization\|Extreme Prematurity\|Early-Onset Neonatal Sepsis\|Late-Onset Neonatal Sepsis\|Necrotizing Enterocolitis of Newborn\|Death; Neonatal	August 5, 2020	Phase 4
NCT00491426	Duke University\|Pediatric Pharmacology Research Units Network	Infection	January 2006
NCT05469984	Western Galilee Hospital-Nahariya	Preterm Labor With Preterm Delivery\|Premature Rupture of Membranes Prolonged	September 2022	Not Applicable
NCT01312792	International Centre for Diarrhoeal Disease Research, Bangladesh\|UNICEF	Pneumonia	August 2010	Not Applicable
NCT01189487	Pfizer	Pneumonia, Bacterial	October 2010	Phase 3
NCT00002052	University of Southern California\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Salmonella Infections		Not Applicable
NCT05051163	Makerere University	HIV-1-infection\|Malnutrition, Child	June 14, 2021	Phase 2\|Phase 3
NCT02384200	University of California, San Diego\|Mayo Clinic\|University of British Columbia\|The Cleveland Clinic\|Duke University\|Ohio State University\|Dartmouth-Hitchcock Medical Center\|Vanderbilt University\|New York University	Nephrolithiasis\|Urinary Tract Infections	March 2015	Phase 4
NCT00814905	United States Naval Medical Center, Portsmouth	Chorioamnionitis	June 2009	Not Applicable
NCT01551394	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Sepsis	September 2012	Phase 3
NCT04041791	University of Oxford\|University of Nairobi\|London School of Hygiene and Tropical Medicine\|National Institute for Health Research, United Kingdom\|Department for International Development, United Kingdom\|Medical Research Council\|Wellcome Trust\|Kenya Ministry of Health	Pneumonia	August 19, 2019	Phase 3
NCT01633294	Hospital de Santa Maria, Portugal	Chorioamnionitis\|Puerperal Endometritis\|Neonatal Early Onset Sepsis\|Neonatal Meningitis\|Neonatal Pneumonia	October 2008	Phase 2\|Phase 3
NCT02477423	University of Chicago	Premature Birth of Newborn\|Enterocolitis, Necrotizing	July 2015	Not Applicable
NCT01433757	University of Florida\|Tyler´s Hope for a Dystonia Cure, Inc	DYT-1\|Dystonia	September 2011	Phase 1
NCT02427932	Stanford University\|David Drover, MD	Drug Metabolism During Pregnancy	May 2015
NCT02007603	Medical University of Vienna	Infection During Hemodialysis	August 2013	Phase 3
NCT02829060	University of California, San Diego	Nephrolithiasis\|Urinary Tract Infection (UTI)\|Sepsis	January 2016	Not Applicable
NCT03248973	Far Eastern Memorial Hospital	Listeria Monocytogenes	April 3, 2017
NCT02865564	University Medical Centre Ljubljana\|University of Ljubljana	Gastrointestinal Diseases\|Colic	November 2016	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

0.1 M NaOH : 25 mg/mL ( 71.55 mM ; Need ultrasonic)

H ₂ O : 5 mg/mL ( 14.31 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8620 mL	14.3102 mL	28.6205 mL
5 mM	0.5724 mL	2.8620 mL	5.7241 mL
10 mM	0.2862 mL	1.4310 mL	2.8620 mL

* Please refer to the solubility information to select the appropriate solvent.

References

Synonyms

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, D-(-)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(D-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-

(2S,5R,6R)-6-[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(-)-6-(2-Amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

6-[D-(-)-α-Aminophenylacetamido]penicillanic acid

Ampicillin

Binotal

Penbritin

Viccillin

Penicline

Aminobenzylpenicillin

Omnipen

D-(-)-α-Aminobenzylpenicillin

D-(-)-α-Aminopenicillin

Penbritin paediatric

Penbritin syrup

Ampicillin acid

Penicillin, (aminophenylmethyl)-

Ampicillin A

Amblosin

Amplital

Austrapen

Britacil

BRL 1341

Doktacillin

Penbristol

Totapen

Amfipen

Nuvapen

Ultrabron

Amplisom

Ampimed

Guicitrina

D-Ampicillin

D-(-)-Ampicillin

6-[D-(-)-2-Amino-2-phenylacetamido]penicillanic acid

Ampicillin anhydrate

Wy 5103

Penbrock

AY 6108

Semicillin

Viccillin S

Tolomol

D-(-)-6-(α-Aminophenylacetamido)penicillanic acid

Ampivet

Amotital

Roscillin

Synpenin

Olin Kid

Ampisyn

Alpen

P 50

Bonapicillin

Grampenil

Copharcilin

Ultrabion

Ampipenin

Totalciclina

Pentrexyl

Totacillin

Ampi-Bol

QIDamp

Tokiocillin

Marisilan

Amipenix S

Ponecil

Adobacillin

Campicillin

Ficillin

Redicilin

Ampi-kel

Polyflex

Polyflex (antibiotic)

Ampicilina

Bacipen

Amipenix

Dumopen

Albipen

Ampitab

Domicillin

NSC 528986

A-Pen

Omnipe

Amcillin

Reichlin

Cincillin

Gobemicina

Britapen

Hiperbiotico

Unacim